| Major Depressive Disorder
Abilify vs Viibyrd
Side-by-side clinical, coverage, and cost comparison for major depressive disorder.Deep comparison between: Abilify vs Viibryd with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsViibryd has a higher rate of injection site reactions vs Abilify based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Viibryd but not Abilify, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abilify
Viibryd
At A Glance
Oral
Once daily
Atypical antipsychotic
Oral
Daily
SSRI / 5-HT1A partial agonist
Indications
- Schizophrenia
- Bipolar I disorder
- Major Depressive Disorder
- Autistic Disorder
- Gilles de la Tourette syndrome
- Major Depressive Disorder
Dosing
Schizophrenia - adults Starting dose 10-15 mg/day, target 10-15 mg/day, max 30 mg/day, once daily without regard to meals.
Schizophrenia - adolescents (13-17 yrs) Starting dose 2 mg/day, titrated to 5 mg after 2 days and target of 10 mg/day after 2 additional days, max 30 mg/day, once daily.
Bipolar I disorder - adults, monotherapy Starting dose 15 mg/day, target 15 mg/day, up to 30 mg/day based on clinical response, once daily.
Bipolar I disorder - adults, adjunct to lithium or valproate Starting dose 10-15 mg/day, target 15 mg/day, max 30 mg/day, once daily.
Bipolar I disorder - pediatric (10-17 yrs) Starting dose 2 mg/day, titrated to 5 mg/day after 2 days and target of 10 mg/day after 2 additional days, max 30 mg/day, once daily.
Major Depressive Disorder - adults, adjunct to antidepressants Starting dose 2-5 mg/day, recommended range 2-15 mg/day, max 15 mg/day, once daily.
Autistic Disorder - pediatric (6-17 yrs), irritability Starting dose 2 mg/day, target 5-10 mg/day, max 15 mg/day, once daily.
Gilles de la Tourette syndrome - pediatric (6-18 yrs) Starting dose 2 mg/day; target 5 mg/day for patients <50 kg (max 10 mg/day) or 10 mg/day for patients >=50 kg (max 20 mg/day), once daily.
Major Depressive Disorder Start at 10 mg once daily with food for 7 days, then increase to 20 mg once daily; may increase up to 40 mg once daily after a minimum of 7 days between dosage increases; target dose is 20-40 mg once daily with food.
Contraindications
- History of hypersensitivity reaction to aripiprazole (reactions have ranged from pruritus/urticaria to anaphylaxis)
- Concomitant use or within 14 days of stopping MAOIs, including linezolid or intravenous methylene blue, due to increased risk of serotonin syndrome
Adverse Reactions
Most common (>=10%) - adults nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia, restlessness
Most common (>=10%) - pediatric somnolence, headache, vomiting, extrapyramidal disorder, fatigue, increased appetite, insomnia, nausea, nasopharyngitis, weight increased
Serious NMS, tardive dyskinesia, metabolic changes, pathological gambling, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, seizures, cerebrovascular adverse events, suicidal thoughts and behaviors
Postmarketing anaphylactic reaction, angioedema, DRESS, blood glucose fluctuation, hiccups, oculogyric crisis, pathological gambling, fecal incontinence
Most common (>=5%) Diarrhea, nausea, vomiting, insomnia
Serious Suicidal thoughts and behaviors, serotonin syndrome, increased risk of bleeding, activation of mania or hypomania, discontinuation syndrome, seizures, angle-closure glaucoma, hyponatremia, sexual dysfunction
Postmarketing Irritability, sleep paralysis, hallucinations, suicide attempt, suicidal ideation, rash, urticaria, drug eruption, acute pancreatitis, anosmia, hyposmia
Pharmacology
Aripiprazole is an atypical antipsychotic whose efficacy may be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors; it also exhibits high affinity for D3, moderate affinity for D4, 5-HT2C, 5-HT7, alpha1-adrenergic, and H1 receptors.
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist thought to enhance serotonergic activity in the CNS through selective inhibition of serotonin reuptake; its exact mechanism in treating major depressive disorder is not fully understood.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abilify
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Viibryd
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (9/12) · Qty limit (1/12)
UnitedHealthcare
Abilify
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Viibryd
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Abilify
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (1/3)
Viibryd
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Abilify.
No savings programs available for Viibryd.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbilifyView full Abilify profile
ViibrydView full Viibryd profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.